Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users

Morbidity and Mortality Weekly Report

Volumn 62, Issue 23, 2013, Pages 463-465

  Smith, Dawn K ^a   Martin, Michael ^a   Lansky, Amy ^a   Mermin, Jonathan ^a   Choopanya, Kachit ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Bangkok Tenofovir Study Group   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ARTICLE; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MALE HOMOSEXUALITY; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SUBSTANCE ABUSE; UNITED STATES;

ADENINE; ANTI-HIV AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DEOXYCYTIDINE; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; ORGANOPHOSPHONATES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 84878998392     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand: a randomized, double-blind, placebo-controlled trial. Lancet. In press, June 2013.
2. CDC. Estimated HIV incidence in the United States, 2007-2010. HIV surveillance supplemental report 2012;17(4). Available at http://www. cdc.gov/hiv/topics/surveillance/resources/reports/#supplemental.
3. CDC. HIV infection and HIV-associated behaviors among injecting drug users-20 cities, United States, 2009. MMWR 2012;61:133-8.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
5. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
6. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
7. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
8. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003) [Abstract]. Presented at the 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA. Available at http://www.retroconference. org/2013b/abstracts/47951.htm.
9. CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011;60:65-8.
10. CDC. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR 2012;61:586-9.
11. Food and Drug Administration. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2012. Available at http://www.fda.gov/ forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ ucm312264.htm.
12. CDC. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR 2012;61(No. RR-5).
13. Edelman EJ, Fiellin DA. Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine. Am J Prev Med 2013;44(1 Suppl 2):S86-90.